|
|
 |
 |
| The Proteins Congress 2009 is administered by Osney Media. |
|
|
|
|
 |
 |
| Next Event |
|
|
The Proteins Congress 2009
Thursday 29th October 2009 to Friday 30th October 2009 Berlin, Germany
|
|
More
|
|
|
|
 |
|
| Oxford Global conferences’ strict delegate screening criteria and one to one meeting selection facility allow you to reach a large number of pre-qualified decision makers and make the most of your time at the event. |
|
Read More
|
|
|
| Speakers |
 |
|
| The Proteins Congress 2009 consists of a unique blend of presentations, panel discussions and one to one business meetings. If you have a cutting edge case study or a thought provoking presentation join us at the event. |
|
Read More
|
|
|
|
|
|
|
|
| Featured Speakers |
|
|
|
Lars Abrahmsén,
Chief Scientific Officer, Affibody AB
|
 |
|
|
Alexandra Alderton,
Primary Pharmacology Group, Pfizer
|
|
|
|
Simon Brack,
Head of Lead Discovery, Covagen AG
|
|
|
|
Nicola Burgess Brown,
Head of Biotechnology, Oxford, The Structural Genomics Consortium
|
|
|
|
Paul Carter,
Investigator, GSK
|
|
|
|
Naomi Chayen,
President of the International Organisation for Biological Crystallization, Department of BioMolecular Medicine, SORA Division, Faculty of Medicine, Imperial College London
|
|
|
|
Giuseppe Ciaramella,
Executive Director Head of Biotherapeutics, Sandwich, Pfizer
|
|
|
|
Jeff Culp,
Associate Research Fellow, Primary Pharmacology Group, Pfizer Global Research & Development
|
|
|
|
Xiao Dan Li,
Structural Biology Group, Paul Scherrer Institute
|
|
|
|
Robert Hayes,
Venture Leader, Centyrex, Johnson & Johnson Ventures
|
|
|
|
Christian Heinis,
Group Head, Laboratory of Therapeutic Peptides and Proteins, Ecole Polytechnique Federal de Lausanne (EPFL)
|
|
|
|
Alistair Henry,
Senior Principal Scientist, Structural Biology, UCB
|
|
|
|
Syd Johnson,
VP, Antibody Engineering, Macrogenics
|
|
|
|
Mathieu Laouenan,
Senior Manager, ACQUITY UPLC Business Development, Europe, Waters
|
|
|
|
John Liddell,
Head of Process Science, Avecia Biologics
|
|
|
|
Tomas Lundqvist,
Director Cell Protein and Structural Sciences (CPSS) DECS, AstraZeneca
|
|
|
|
Felix Oehme,
Biotech Development, Bayer Schering Pharma AG
|
|
|
|
Sigurd Okkels,
Vice President, Biologics Department, Discovery and Proof of Concept Development, Nycomed GmbH
|
|
|
|
Søren K. Rasmussen,
Senior Scientist, Antibody Expression, Symphogen A/S
|
|
|
|
Aaron Sato,
Senior Director of Antibody Engineering, OncoMed Pharmaceuticals
|
|
|
|
Arne Skerra,
Professor of Biological Chemistry, Technische Universitaet Muenchen, Freising-Weihenstephan, Germany
|
|
|
|
Peter Sondermann,
CSO, SuppreMol GmbH
|
|
|
|
Klaus Strein,
Head Pharmaceutical Research, Penzberg (Germany), F. Hoffmann-La Roche
|
|
|
|
Dominic Tisi,
Senior Scientist, Astex Therapeutics
|
|
|
|
David Urech,
Head of R&D, ESBA Tech
|
|
|
|
Paul Watt,
Vice President Drug Discovery, Phylogica
|
|
|
|
Trevor Wilkinson,
Head of Protein Sciences, MedImmune
|
|
|
|
Yuan Xu,
Global Head/VP of Process Sciences and Production, Novartis Biologics
|
|
|
|
|
|
|
|
|
|
